EMD Serono — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

EMD Serono is a well-established, commercial-stage biopharmaceutical company and a key regional pillar of the global Merck KGaA healthcare group. With a legacy dating back to 1971, it has built a strong commercial presence in high-need therapeutic areas, particularly reproductive health, neurology, and oncology. The company's strategy involves commercializing the global parent's pipeline in North America while also engaging in targeted business development to expand its portfolio. As a subsidiary of a large, diversified multinational, it benefits from significant R&D resources and financial stability while focusing on specialty care markets with significant unmet needs.

OncologyNeurologyReproductive HealthImmunology

Technology Platform

Leverages global Merck KGaA R&D platforms across biologics (monoclonal antibodies) and small molecules, with focused expertise in immuno-oncology, neuroimmunology, and reproductive endocrinology.

Opportunities

Significant near-term growth potential from the launch of late-stage pipeline assets in oncology (e.g., xevinapant) and multiple sclerosis (evobrutinib) in the large North American market.

The stable, recession-resilient fertility business provides a consistent revenue foundation.

Leveraging the global R&D scale of Merck KGaA allows for sustained pipeline innovation.

Risk Factors

Heavy reliance on the success of a few key late-stage clinical candidates; failure would impair growth.

Intense competition in core markets (MS, oncology) pressures pricing and market share.

Exposure to potential US drug pricing reforms and ongoing payer pressure on specialty drug costs.

Competitive Landscape

In oncology, EMD Serono competes with large pharma (Merck & Co., Bristol-Myers Squibb, Roche) and biotechs in the immuno-oncology space, often focusing on niche indications. In multiple sclerosis, it faces a crowded market dominated by Biogen, Novartis, Roche, and Sanofi. In fertility, it competes with other large players like Ferring Pharmaceuticals and Organon.

More companies in United States →